M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice
Gervasio A. Lamas,Marc A. Pfeffer,Peggy Hamm,John H. Wertheimer,Jean-Lucien Rouleau,Eugene Braunwald +5 more
TL;DR: It is suggested that randomized clinical trials have a measurable influence on medical practice patterns and changes in treatment practices for this disorder.
Journal ArticleDOI
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Michael A. Blazing,James A. de Lemos,Harvey D. White,Keith A.A. Fox,Freek W.A. Verheugt,Diego Ardissino,Peter M. DiBattiste,Joanne Palmisano,David W. Bilheimer,Steven M. Snapinn,Karen E. Ramsey,Laura H. Gardner,Vic Hasselblad,Marc A. Pfeffer,Eldrin F. Lewis,Eugene Braunwald,Robert M. Califf +16 more
TL;DR: In patients receiving tirofiban and aspirin, enoxaparin is a suitable alternative to unfractionated heparin for treatment of non-ST-elevation ACS and is consistent with prior trials performed without the use of glycoprotein IIb/IIIa inhibitors.
Journal ArticleDOI
Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure
Wendy Johnson,Torbjørn Omland,Christian Hall,Caroline Lucas,Ole L Myking,Caroline M. Collins,Marc A. Pfeffer,Jean-Lucien Rouleau,Lynne W. Stevenson +8 more
TL;DR: Neural activation rapidly decreases after short-term therapy tailored to decrease severely elevated filling pressures and SVR without inotropic agents, and therapy designed to address neurohormonal activation should include therapy to improve severe resting hemodynamic compromise.
Journal ArticleDOI
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk : The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Jeff S. Healey,Robert G. Hart,Janice Pogue,Marc A. Pfeffer,Stefan H. Hohnloser,Raffaele De Caterina,Greg C. Flaker,Salim Yusuf,Stuart J. Connolly +8 more
TL;DR: Patients with a CHADS2=1 had a low risk of stroke, yet still derived a modest but statistically significant absolute reduction in stroke with OAC and had low rates of major hemorrhage on OAC.
Journal ArticleDOI
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial
Sandra J. Lewis,Frank M. Sacks,Jayne Mitchell,Cara East,Stephen P. Glasser,Sheren Kell,Rebecca Letterer,Marian C. Limacher,Lemuel A. Moyé,Jean L. Rouleau,Marc A. Pfeffer,Eugene Braunwald +11 more
TL;DR: Pravastatin led to significant early reduction of a wide range of cardiovascular events in post-MI women with average cholesterol levels and improved plasma lipids similarly in men and women.